Stock listing
LSE:ONT Oxford Nanopore Technologies PLC Share Price
Home listing (LSE) of Oxford Nanopore Technologies PLC
Follow Oxford Nanopore Technologies PLC into a list and get an email when it puts out news.
Share price · LSE:ONT
188.70p GBX (pence) -7.90 (-4.0%)
Close on Nov 20, 2026
- Day range
- 186.90p – 198.00p GBX (pence)Nov 20, 2026
- Volume
- 950,534 sharesNov 20, 2026
- Market cap
- £1.85B GBPAt the close on Nov 20, 2026 · price × 980.9M shares outstanding
- 52-week range
- 95.61p – 239.40p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £5.61M GBPMedian day 1.80M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:ONT · Home | 188.70p GBX (pence) | -7.90 (-4.0%) | 950,534 | 198.00p | 198.00p | 186.90p | 196.60p | Close on Nov 20, 2026 |
| OTC:ONTTF | $2.50 USD | -0.20 (-7.4%) | 500 | $2.50 | $2.50 | $2.50 | $2.70 | Close on Nov 20, 2026 |
| OTC:OXFYY | $10.84 USD | -0.595 (-5.2%) | 1,000 | $10.84 | $10.84 | $10.84 | $11.43 | Close on Nov 18, 2026 |
| Frankfurt:4R0 | €2.364 EUR | -0.008 (-0.3%) | — | €2.266 | €2.364 | €2.266 | €2.372 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:ONT · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 188.70p | -7.90 | -4.0% | 198.00p | 198.00p | 186.90p | 950,534 | |
| 196.60p | -0.70 | -0.4% | 197.70p | 204.40p | 195.90p | 552,943 | |
| 197.30p | -6.90 | -3.4% | 201.00p | 203.56p | 195.70p | 1,483,997 | |
| 204.20p | +5.20 | +2.6% | 199.00p | 205.20p | 197.50p | 1,042,952 | |
| 199.00p | -2.40 | -1.2% | 199.00p | 202.80p | 196.80p | 1,103,552 | |
| 201.40p | -3.80 | -1.9% | 203.80p | 206.18p | 194.78p | 1,250,419 | |
| 205.20p | +4.20 | +2.1% | 203.60p | 206.82p | 202.54p | 714,830 | |
| 201.00p | -9.40 | -4.5% | 213.00p | 213.00p | 201.00p | 1,756,986 | |
| 210.40p | +4.60 | +2.2% | 207.80p | 213.20p | 205.80p | 1,683,223 | |
| 205.80p | +1.00 | +0.5% | 202.00p | 206.80p | 198.64p | 965,632 | |
| 204.80p | -5.60 | -2.7% | 210.40p | 213.80p | 199.90p | 1,820,314 | |
| 210.40p | -5.40 | -2.5% | 217.80p | 220.00p | 209.60p | 1,853,810 | |
| 215.80p | +2.80 | +1.3% | 210.00p | 218.80p | 205.20p | 1,220,795 | |
| 213.00p | -9.60 | -4.3% | 227.80p | 227.80p | 211.20p | 1,201,805 | |
| 222.60p | -10.80 | -4.6% | 230.00p | 232.67p | 222.40p | 1,661,458 | |
| 233.40p | -1.60 | -0.7% | 233.20p | 237.00p | 230.00p | 876,778 | |
| 235.00p | +9.40 | +4.2% | 225.80p | 239.40p | 222.69p | 2,874,360 | |
| 225.60p | +10.60 | +4.9% | 214.20p | 225.60p | 210.60p | 1,335,239 | |
| 215.00p | +4.60 | +2.2% | 209.80p | 215.00p | 207.60p | 1,050,544 | |
| 210.40p | -1.00 | -0.5% | 210.20p | 213.20p | 205.40p | 869,396 | |
| 211.40p | -4.80 | -2.2% | 214.40p | 220.00p | 211.00p | 1,178,092 | |
| 216.20p | +7.40 | +3.5% | 208.60p | 216.20p | 204.00p | 4,650,405 | |
| 208.80p | -0.40 | -0.2% | 210.00p | 213.00p | 201.00p | 1,808,136 | |
| 209.20p | +9.20 | +4.6% | 200.40p | 210.20p | 200.20p | 1,790,959 | |
| 200.00p | -9.60 | -4.6% | 208.40p | 215.60p | 196.60p | 3,219,887 | |
| 209.60p | +1.00 | +0.5% | 206.60p | 212.00p | 204.20p | 1,073,336 | |
| 208.60p | -2.40 | -1.1% | 212.00p | 212.80p | 203.60p | 1,675,885 | |
| 211.00p | -6.00 | -2.8% | 218.80p | 219.80p | 211.00p | 2,840,056 | |
| 217.00p | +3.60 | +1.7% | 216.40p | 218.80p | 212.20p | 1,442,846 | |
| 213.40p | +12.60 | +6.3% | 203.60p | 213.60p | 199.80p | 4,107,852 | |
| 200.80p | -19.80 | -9.0% | 217.00p | 219.00p | 198.40p | 3,451,283 | |
| 220.60p | -10.20 | -4.4% | 227.20p | 227.40p | 212.20p | 6,585,249 | |
| 230.80p | +10.80 | +4.9% | 220.00p | 238.80p | 219.60p | 5,725,027 | |
| 220.00p | -3.20 | -1.4% | 221.00p | 227.00p | 212.20p | 2,819,793 | |
| 223.20p | +9.20 | +4.3% | 211.00p | 237.00p | 207.80p | 7,474,316 | |
| 214.00p | -3.60 | -1.7% | 218.80p | 220.80p | 206.50p | 14,809,223 | |
| 217.60p | +18.20 | +9.1% | 201.80p | 218.60p | 187.35p | 5,281,206 | |
| 199.40p | +16.90 | +9.3% | 182.70p | 201.60p | 178.79p | 4,928,150 | |
| 182.50p | +0.90 | +0.5% | 182.00p | 187.40p | 179.10p | 2,381,529 | |
| 181.60p | +8.10 | +4.7% | 175.00p | 182.20p | 173.80p | 2,057,090 | |
| 173.50p | -2.00 | -1.1% | 175.00p | 178.65p | 172.30p | 1,486,640 | |
| 175.50p | -2.50 | -1.4% | 175.00p | 180.34p | 175.00p | 5,485,120 | |
| 178.00p | +5.80 | +3.4% | 173.90p | 180.00p | 173.60p | 1,800,697 | |
| 172.20p | -2.20 | -1.3% | 174.50p | 177.30p | 172.20p | 3,540,149 | |
| 174.40p | +3.60 | +2.1% | 167.80p | 179.00p | 167.80p | 3,615,869 | |
| 170.80p | +9.50 | +5.9% | 162.20p | 171.30p | 161.40p | 1,876,808 | |
| 161.30p | +3.00 | +1.9% | 159.80p | 163.40p | 157.10p | 1,349,539 | |
| 158.30p | +4.30 | +2.8% | 152.90p | 158.60p | 152.90p | 1,797,254 | |
| 154.00p | -2.90 | -1.8% | 156.10p | 157.80p | 152.10p | 1,076,812 | |
| 156.90p | +4.20 | +2.8% | 154.00p | 158.60p | 151.20p | 1,044,315 | |
| 152.70p | -5.50 | -3.5% | 156.90p | 161.10p | 148.00p | 3,267,741 | |
| 158.20p | -0.60 | -0.4% | 157.20p | 160.10p | 155.40p | 1,693,633 | |
| 158.80p | +1.30 | +0.8% | 160.00p | 161.30p | 155.10p | 1,111,150 | |
| 157.50p | -3.90 | -2.4% | 160.20p | 163.00p | 155.20p | 1,441,965 | |
| 161.40p | -11.90 | -6.9% | 153.00p | 166.80p | 152.70p | 8,433,103 | |
| 173.30p | +3.30 | +1.9% | 172.00p | 180.30p | 169.40p | 1,759,649 | |
| 170.00p | +10.00 | +6.3% | 160.00p | 173.00p | 157.70p | 1,666,855 | |
| 160.00p | -16.10 | -9.1% | 172.60p | 175.30p | 158.50p | 2,593,195 | |
| 176.10p | -5.10 | -2.8% | 180.00p | 183.80p | 175.80p | 4,476,288 | |
| 181.20p | -0.60 | -0.3% | 184.10p | 191.40p | 181.20p | 3,093,883 | |
| 181.80p | -1.20 | -0.7% | 182.80p | 184.40p | 176.10p | 3,331,648 | |
| 183.00p | +16.30 | +9.8% | 166.20p | 183.00p | 163.90p | 3,852,920 | |
| 166.70p | -3.30 | -1.9% | 173.20p | 179.20p | 164.80p | 4,811,008 | |
| 170.00p | +5.50 | +3.3% | 164.50p | 170.00p | 157.10p | 7,900,456 | |
| 164.50p | +24.80 | +17.8% | 141.90p | 164.50p | 140.95p | 10,579,945 |
- Ticker
- LSE:ONT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Nov 18, 2026
Grant of LTIP awards; Director/PDMR Notification
Latest deck · Aug 19, 2026
H1 2026 Earnings Presentation
Earnings · 46 slides
Latest news
Grant of LTIP awards; Director/PDMR Notification
Nov 18, 2026
Closed 188.70p (-4.0%) on Nov 20, 2026
Share Incentive Plan - Director/PDMR Shareholding
Nov 12, 2026
Closed 199.00p (-1.2%) on Nov 13, 2026
Participation in upcoming investor conferences
Nov 4, 2026
Closed 210.40p (-2.5%) on Nov 4, 2026
Issue of Equity and Total Voting Rights
Nov 2, 2026
Closed 215.80p (+1.3%) on Nov 3, 2026
Appointment of Chief Business Development Officer
Oct 20, 2026
Closed 208.80p (-0.2%) on Oct 20, 2026
Director/PDMR Shareholding
Oct 12, 2026
Closed 211.00p (-2.8%) on Oct 13, 2026
IP Group completes partial realisation in ONT
Oct 2, 2026
Closed 223.20p (+4.3%) on Oct 2, 2026
Holding(s) in Company
Oct 2, 2026
Closed 223.20p (+4.3%) on Oct 2, 2026
Preliminary injunction against MGI Tech GmbH
Sep 16, 2026
Closed 161.30p (+1.9%) on Sep 16, 2026
Appointment of CDPO
Aug 25, 2026
Closed 183.00p (+9.8%) on Aug 25, 2026
Oxford Nanopore Technologies PLC on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 33 in the last 12 months · 193 in all · newest Nov 18, 2026 · oldest 2000
- Decks
- 15 decks · latest Aug 19, 2026
Where Oxford Nanopore Technologies PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:ONT · Home listing · This page | LSE | United Kingdom | GBX |
| gettex:4R0 | gettex | Germany | EUR |
| OTC:ONTTF | OTC | United States | USD |
| LS Exchange:A3C307 | LS Exchange | Germany | EUR |
| OTC:OXFYY | OTC | United States | USD |
| Tradegate:4R0 | Tradegate | Germany | EUR |
| Lang & Schwarz:A3C307 | Lang & Schwarz | Germany | EUR |
| Aquis:ONTL | Aquis | United Kingdom | GBX |
| Turquoise:ONTL | Turquoise | United Kingdom | GBX |
| Frankfurt:4R0 | Frankfurt | Germany | EUR |
| Stuttgart:4R0 | Stuttgart | Germany | EUR |
| Dusseldorf:4R0 | Dusseldorf | Germany | EUR |
| Hamburg:4R0 | Hamburg | Germany | EUR |
| Munich:4R0 | Munich | Germany | EUR |
| Hanover:4R0 | Hanover | Germany | EUR |
| Xetra:4R0 | Xetra | Germany | EUR |
Valuation
EV/sales 7.6× against a median of 5.3×: 7th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £1.71B GBP
- P/E
- Loss
- EV/sales
- 7.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.4×
- Gross margin
- 58.6%
- Operating margin
- −69.4%
- Net margin
- −64.8%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oxford Nanopore Technologies PLC · LSE:ONT | US$2.42B | US$2.23B | n/a | 7.6× | n/a | 4.4× | −64.8% | 0.1× | n/a |
| Joinn Laboratories (China) Co., Ltd. Class A · SSE:603127 | US$3.04B | US$2.66B | 17.7× | 9.6× | n/a | 2.2× | 61.6% | 0.0× | n/a |
| MGI Tech Co., Ltd. Class A · SSE:688114 | US$2.92B | US$2.53B | n/a | 5.5× | n/a | 2.8× | −9.5% | 0.2× | n/a |
| Neuland Laboratories Ltd. · NSE:NEULANDLAB | US$2.86B | US$2.80B | 58.5× | 11.3× | 36.8× | 13.1× | 19.6% | 0.2× | n/a |
| Shanghai Haoyuan Chemexpress Co. Ltd. Class A · SSE:688131 | US$2.72B | US$2.61B | 56.7× | 5.0× | n/a | 5.3× | 9.3% | 0.3× | n/a |
| Veracyte, Inc. · NASDAQ:VCYT | US$2.03B | US$1.70B | 16.0× | 2.9× | 14.0× | 1.4× | 21.8% | 0.0× | 1.34 |
| OneSource Specialty Pharma Limited · NSE:ONESOURCE | US$1.99B | US$2.18B | n/a | 12.0× | 50.9× | 3.1× | −0.1% | 0.3× | n/a |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456 | US$1.97B | US$1.77B | 22.0× | 2.2× | n/a | 1.5× | 11.3% | 0.0× | n/a |
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Median of the others | US$2.01B | US$2.07B | 56.7× | 5.3× | 36.8× | 3.0× | 7.3% | 0.1× | 1.47 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 223.25 GBX · Analysts' mean
- EPS, year to Dec 2026
- -0.10 · 9 analysts
- Revenue, year to Dec 2026
- 269.6M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Francis Van Parys | Chief Executive Officer |
| Nick Keher | Chief Financial Officer |
| Hannah Coote | Vice President, Associate General Counsel |
| Jordan Herman | SVP, General Counsel |
| Alvaro Correia | VP, Global Supply Chain |
| Ant Jones | VP, Engineering |
| Chris Hannan | VP, Quality Assurance and Regulatory Affairs |
| David Stoddart | VP, Sample Technology |
| Gretchen Weightman | VP & GM, APAC |
| Jayne Wallace | VP, Nanopore Research and Protein Sequencing |
| Jeremy Bryar | VP, Manufacturing |
| Kristen Stoops | VP, Strategic Marketing and Business Development |
| Martyn Andrews | VP, Intellectual Property |
| Nirmala Santiapillai | VP, Commercial Operations |
| Oliver Hartwell | VP, Strategic Planning |
| Phil Watkins | VP, Finance |
| Rhodri Davies | VP, Operations |
| Sarah Woods | VP, Global IT |
| Sissel Juul | VP, Applications |
| Stephanie Abernathy | VP, Commercial |
| Thomas Bray | VP, Business Development |
| Tonya McSherry | VP Commercial, EMEAI |
| Andrew Watson | Chief Information Officer |
| Conor McKechnie | Chief Marketing and Communications Officer |
| David Miller | Chief Development and Product Officer |
| Davide Manissero | Chief Medical Officer |
| Lakmal Jayasinghe | Chief Scientific Officer |
| Sebastian Kronmueller | Chief Business Development Officer |
| Tina St. Leger | Chief People Officer |
Board
| Director | Role |
|---|---|
| Duncan Tatton-Brown | Chairman of the Board |
| Adrian Hennah | Non-executive Director |
| Daniel Mahony | Non Executive Director |
| Francis Van Parys | Chief Executive Officer |
| Heather Preston | Non Executive Director |
| John O'Higgins | Non-executive Director |
| Kate Priestman | Non Executive Director |
| Nick Keher | Chief Financial Officer |
| Sarah Fortune | Non Executive Director |
Events
- Next results
- Mar 3, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 2, 2025 · After close | +1.2% |
| Quarter to Mar 31, 2025 | Jun 10, 2025 · After close | +0.8% |
| Q4 2022 | Mar 21, 2023 | +12.0% |
| Q2 2022 | Sep 13, 2022 | +8.3% |
| Q4 2021 | Mar 22, 2022 | −5.9% |
| Q2 2021 | Sep 30, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 46 slides | Aug 19, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 18 slides | Jan 12, 2026 |
| H1 2025 Earnings Presentation | Earnings | 30 slides | Sep 2, 2025 |
| FY2024 Earnings Presentation | Earnings | 41 slides | Mar 4, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 27 slides | Jan 13, 2025 |
| H1 2024 Earnings Presentation | Earnings | 32 slides | Sep 3, 2024 |
| FY2023 Earnings Presentation | Earnings | 42 slides | Mar 6, 2024 |
| JPM 2024 | Conference | 30 slides | Jan 9, 2024 |
| Investor Day (October 2023) | Investor day | 171 slides | Oct 19, 2023 |
| H1 2023 Earnings Presentation | Earnings | 36 slides | Sep 6, 2023 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2022 Earnings Presentation | Earnings | 38 slides | Mar 21, 2023 |
| H1 2022 Earnings Presentation | Earnings | 33 slides | Sep 13, 2022 |
| FY2021 Earnings Presentation | Earnings | 36 slides | Mar 22, 2022 |
| JP Morgan Healthcare Conference January 2022 | Conference | 27 slides | January 2022 |
| ESG Presentation (September 2021) | Sustainability | 8 slides | September 2021 |
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 223.9M | 183.2M | 169.7M | 198.6M | 133.7M | 113.9M | 52.1M | 32.5M | 13.8M | 4.53M |
| Cost of revenue | 92.6M | 77.8M | 79.2M | 74.8M | 60.5M | 67.0M | 26.4M | 16.5M | 7.06M | 3.88M |
| Gross profit | 131.3M | 105.4M | 90.5M | 123.8M | 73.2M | 46.9M | 25.6M | 16.0M | 6.73M | 645.0K |
| Research and development | 97.7M | 98.9M | 103.8M | 69.2M | 76.0M | 48.6M | 40.5M | 37.1M | 35.0M | 38.1M |
| Selling, general and administrative | 188.9M | 158.8M | 155.2M | 157.4M | 161.8M | 71.4M | 66.1M | 41.1M | 23.6M | |
| Operating income | -155.3M | -152.3M | -168.6M | -98.5M | -164.5M | -73.1M | -80.9M | -62.2M | -65.9M | -65.0M |
| Depreciation and amortization | 49.8M | 43.3M | 41.6M | 31.9M | 24.7M | 17.3M | 14.8M | 6.36M | 1.79M | 1.34M |
| EBITDA | -105.5M | -109.0M | -127.0M | -66.6M | -139.8M | -55.7M | -66.0M | -55.8M | -64.1M | -63.6M |
| Interest expense | 2.80M | 3.60M | 2.21M | 1.63M | 908.0K | 747.0K | 614.0K | 423.0K | 0 | |
| Income before tax | -139.9M | -140.0M | -149.8M | -83.4M | -166.0M | -73.2M | -80.5M | -62.0M | -65.9M | -64.7M |
| Income tax | 5.30M | 6.20M | 4.74M | 7.61M | 1.61M | -11.9M | -8.27M | -8.91M | -9.33M | -5.58M |
| Net income | -145.2M | -146.2M | -154.5M | -91.0M | -167.6M | -61.2M | -72.2M | -53.1M | -56.5M | -59.1M |
| Earnings per share, basic | -0.15 | -0.16 | -0.19 | 0.11 | 0.23 | -0.08 | -0.09 | -0.07 | -0.10 | -0.11 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 181.1M | 199.5M | 220.5M | 356.8M | 487.8M | 80.9M | 13.1M | 35.3M | 57.8M | 64.1M |
| Short-term investments | 74.2M | 138.9M | 49.5M | 119.4M | 130.6M | 58.0M | 10.0M | 60.0M | ||
| Receivables | 72.4M | 62.7M | 61.5M | 62.9M | 54.8M | 52.2M | 66.0M | 12.7M | 4.50M | 1.39M |
| Inventory | 81.5M | 99.5M | 101.5M | 87.7M | 63.1M | 35.6M | 20.0M | 18.6M | 6.45M | 340.0K |
| Current assets | 420.0M | 520.1M | 447.2M | 638.0M | 750.6M | 203.2M | 104.5M | 142.3M | 97.9M | 155.5M |
| Property, plant and equipment | 61.9M | 66.3M | 49.9M | 37.3M | 47.2M | 53.2M | 43.4M | 26.5M | 21.4M | |
| Total assets | 622.5M | 742.0M | 777.1M | 823.9M | 841.9M | 281.2M | 164.7M | 175.2M | 119.3M | 158.9M |
| Accounts payable | 108.9M | 102.3M | 78.4M | 80.2M | 72.9M | 31.0M | 12.0M | 10.5M | 3.64M | 3.73M |
| Current liabilities | 118.0M | 111.5M | 89.2M | 91.5M | 105.0M | 72.2M | 36.7M | 21.8M | 15.2M | 13.7M |
| Long-term debt | 0 | 9.50M | 9.50M | 9.50M | 9.50M | |||||
| Total debt | 41.5M | 46.0M | 41.7M | 0 | 9.50M | 23.6M | 19.1M | 9.50M | 9.50M | |
| Total liabilities | 159.2M | 155.7M | 133.2M | 130.3M | 137.9M | 95.3M | 55.2M | 32.3M | 25.7M | 13.7M |
| Shareholders' equity | 463.3M | 586.3M | 643.9M | 693.6M | 704.0M | 185.9M | 109.5M | 142.9M | 93.6M | 144.2M |
| Shares outstanding | 961.0M | 897.8M | 834.0M | 823.7M | 821.6M | 794.7M | 794.7M | 794.7M | 541.1M | 539.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -70.6M | -109.9M | -137.3M | -63.8M | -53.2M | -63.8M | -48.7M | -55.5M | -66.3M | -51.2M |
| Capital spending | -3.50M | -13.9M | -5.91M | -8.63M | -21.5M | -26.5M | -30.3M | -17.8M | -19.7M | -3.03M |
| Free cash flow | -74.1M | -123.8M | -143.2M | -72.5M | -74.7M | -90.3M | -79.0M | -73.3M | -86.1M | -54.2M |
| Cash from investing | 56.3M | 15.0M | -61.8M | -51.4M | -162.0M | -26.9M | 28.5M | -65.4M | -19.6M | -2.50M |
| Cash from financing | -2.10M | 73.6M | 64.7M | -13.7M | 622.9M | 158.6M | -1.99M | 98.4M | 79.7M | 65.1M |
| Share buybacks | 164.0M | 276.0K | 100.3M | |||||||
| Change in cash | -16.4M | -21.3M | -134.4M | -128.9M | 407.7M | 67.8M | -22.2M | -22.5M | -6.28M | 11.5M |
Cap table
Built by 6ix from Oxford Nanopore Technologies PLC’s releases
- Common shares
- 980,902,212
- Fully diluted
- 980,902,212
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 980,902,212 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 980,902,212 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heather Preston Other companies: Aligos Therapeutics, Inc. (Director · Since at least Aug 7, 2024); Akouos Inc (Director · Jun 25, 2020 – Nov 30, 2022 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Jun 24, 2021 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jun 19, 2019 · Past); Albireo Pharma Inc (Director · Nov 3, 2016 – Jan 23, 2017 · Past); Otonomy Inc (Director · Aug 12, 2014 – Jun 11, 2019 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past) | Non Executive Director · Since at least May 1, 2026 |
| Adrian Hennah Other companies: Unilever PLC (Non-Executive Director · Since at least May 13, 2026) | Non-executive Director · Since at least Oct 12, 2026 |
| Francis Van Parys Other companies: Danaher Corporation (Chief Executive Officer · Dec 8, 2025 – Nov 5, 2026 · Past) | Chief Executive Officer · Since at least Oct 20, 2026 |
| John O'Higgins Other companies: Technip Energies NV (Independent Director, Chair of the Board and Chair of the Nomination and Governance Committee · Since at least Apr 30, 2026) | Non-executive Director · Since at least May 1, 2026 |
| Alvaro Correia | VP, Global Supply Chain · Since at least Nov 4, 2026 |
| Andrew Watson | Chief Information Officer · Since at least Aug 19, 2026 |
| Ant Jones | VP, Engineering · Since at least Nov 4, 2026 |
| Chris Hannan | VP, Quality Assurance and Regulatory Affairs · Since at least Nov 4, 2026 |
| Conor McKechnie | Chief Marketing and Communications Officer · Since at least Aug 25, 2026 |
| Daniel Mahony | Non Executive Director · Since at least May 1, 2026 |
All 36 people
| Person | Seat |
|---|---|
| Davide Manissero | Chief Medical Officer · Since at least Aug 19, 2026 |
| David Miller | Chief Development and Product Officer · Since at least Aug 25, 2026 |
| David Stoddart | VP, Sample Technology · Since at least Nov 4, 2026 |
| Duncan Tatton-Brown | Chairman of the Board · Since at least May 1, 2026 |
| Gretchen Weightman | VP & GM, APAC · Since at least Mar 17, 2026 |
| Hannah Coote | Vice President, Associate General Counsel · Since at least Aug 19, 2026 |
| Jayne Wallace | VP, Nanopore Research and Protein Sequencing · Since at least Nov 4, 2026 |
| Jeremy Bryar | VP, Manufacturing · Since at least Nov 4, 2026 |
| Jordan Herman | SVP, General Counsel · Since at least Nov 5, 2026 |
| Kate Priestman | Non Executive Director · Since at least May 1, 2026 |
| Kristen Stoops | VP, Strategic Marketing and Business Development · Since at least Nov 4, 2026 |
| Lakmal Jayasinghe | Chief Scientific Officer · Since at least Mar 4, 2025 |
| Martyn Andrews | VP, Intellectual Property · Since at least Nov 4, 2026 |
| Nick Keher | Chief Financial Officer · Since at least Oct 14, 2026 |
| Nirmala Santiapillai | VP, Commercial Operations · Since at least Nov 4, 2026 |
| Oliver Hartwell | VP, Strategic Planning · Since at least Nov 4, 2026 |
| Phil Watkins | VP, Finance · Since at least Nov 4, 2026 |
| Rhodri Davies | VP, Operations · Since at least Nov 4, 2026 |
| Sarah Fortune | Non Executive Director · Since at least May 1, 2026 |
| Sarah Woods | VP, Global IT · Since at least Nov 4, 2026 |
| Sebastian Kronmueller | Chief Business Development Officer · Since at least Oct 20, 2026 |
| Sissel Juul | VP, Applications · Since at least Nov 4, 2026 |
| Stephanie Abernathy | VP, Commercial · Since at least Nov 4, 2026 |
| Thomas Bray | VP, Business Development · Since at least Nov 4, 2026 |
| Tina St. Leger | Chief People Officer · Since at least Aug 19, 2026 |
| Tonya McSherry | VP Commercial, EMEAI · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Oxford Nanopore Technologies PLC.